Wave Life Sciences, Inc. - Common Stock (NQ:WVE)

WAVE Life Sciences (NASDAQ:WVE) used its 2026 Research Day to outline plans for WVE-008, an RNA-editing candidate being developed for liver disease associated with the PNPLA3 I148M genetic variant,...

WAVE Life Sciences Targets Genetic Liver Disease With WVE-008 RNA Editing Program ↗

November 04, 2026

Performance

52-Week Range 84.4% below 52-week high

3.395

3.0452W Low 21.7352W High

1 Week 10.2% below 1-week high

3.181W Low 3.781W High

Wave Life Sciences, Inc. - Common Stock (WVE) traded between $3.04 and $21.73 over the past 52 weeks and last traded at $3.40, 84.4% below its 52-week high. Over the past week it ranged between $3.18 and $3.78.

Past 12 Months

-3.6%

-1.9%

-44.1%

-52.0%

-78.7%

-51.8%

1W -$0.12

1M -$0.06

3M -$2.68

6M -$3.68

YTD -$12.55

1Y -$3.65

WVE was -51.8% over the past year, -52.0% over six months, -78.7% year to date, -3.6% in the last week.

12 Months vs Market

WVE

-51.8%

DIA

+10.4%

SPY

+10.4%

QQQ

+8.5%

IWM

+15.5%

Over the past 12 months WVE returned -51.8% versus DIA (Dow) +10.4%, SPY (S&P 500) +10.4%, QQQ (Nasdaq 100) +8.5% and IWM (Russell 2000) +15.5%.

Volume & Liquidity 0.64× 3-mo avg

Today 2,126,122 3-mo avg 3.3M

3.2M

3.1M

3.3M

YTD

3.7M

4.4M

WVE most recently traded 2,126,122 shares against a 3-month average daily volume of 3.3M.

More News

Wave Life Sciences (WVE) Q3 2026 Earnings Call Transcript ↗

October 27, 2026

Wave Life Sciences (NASDAQ:WVE) Plunges After Q2 Revenue Miss ↗

July 30, 2026

Via Chartmill

WAVE Life Sciences Q3 Earnings Call Highlights ↗

October 27, 2026

Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update

October 27, 2026

WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path ↗

October 21, 2026

Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026

October 20, 2026

Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026

October 19, 2026

Wave Life Sciences to Present at Chardan’s 10th Annual Healthcare Conference

October 13, 2026

Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD

October 01, 2026

Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development

September 30, 2026

Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity

September 23, 2026

Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer

September 22, 2026

Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

September 03, 2026

Wave Life Sciences Announces Completion of Redomiciliation to Delaware

August 10, 2026

Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware

August 05, 2026

Wave Life Sciences to Present at Upcoming Investor Conferences

August 04, 2026

Wave Life Sciences (WVE) Q2 2026 Earnings Call Transcript ↗

August 03, 2026

Wave Life Sciences (WVE) Q2 2026 Earnings Call Transcript ↗

July 30, 2026

WAVE Life Sciences Q2 Earnings Call Highlights ↗

July 30, 2026

Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

July 30, 2026

Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026

July 23, 2026

Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation

July 07, 2026

Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases

June 24, 2026